Primary pancreatic lymphoma: Report of 4 cases with literature review

Lamrani, Fatima Zahra; Amri, Fakhrddine; Koulali, Hajar; Mqaddem, Ouiam El; Zazour, Abdelkrim; Bennani, Amal; Ismaili, Zahi; Kharrasse, Ghizlane

doi:10.1016/j.radcr.2023.09.067

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В случае повышенного риска осложнений, связанных с биопсией, следует выполнить тонкоигольную пункцию образования (чрескожную или эндоскопическую) и получить материал для цитологического анализа. Отрицательный результат биопсии при положительных данных лучевого исследования -повод для повторных процедур, пока не будет получен диагностически значимый материал [12].…”

Section: Introductionunclassified

Lymphoproliferative disease: could they be localized in the pancreas?

Dinikin

2024

jour

View full text Add to dashboard Cite

Primary involvement of the pancreas in non-Hodgkin’s lymphoma is very rare. The symptoms of the tumor are nonspecific, and the results of instrumental diagnostics are often similar to pancreatic adenocarcinoma. Considering the fundamental differences in approaches to treatment and prognosis of these diseases, making an accurate diagnosis is only possible through morphological examination of tumor tissue samples. The difficulty of collecting a sufficient number of tissue samples, especially for immunohistochemical analysis, and the need for repeated tumor biopsies, in some cases lead to unnecessary surgical interventions.

show abstract

Section: Introductionunclassified

Lymphoproliferative disease: could they be localized in the pancreas?

Dinikin

2024

jour

View full text Add to dashboard Cite

show abstract

“…Only 0.1% of malignant lymphomas, 0.6% of extranodal lymphomas, and 0.2% of all pancreatic malignancies are caused by primary pancreatic lymphoma (PPL)[ 7 , 8 ]. The most prevalent type of PPL is diffuse large B-cell lymphoma (DLBCL), which potentially presents as other lymphomas; however, cases of PTCL-NOS, which are non-Hodgkin's lymphoma and T-cell lymphoma, are even rarer than are other types of PPL[ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Primary pancreatic peripheral T-cell lymphoma: A case report

Bai,

Wang,

Luo

et al. 2024

World J Gastrointest Oncol

View full text Add to dashboard Cite

BACKGROUND Primary pancreatic lymphoma (PPL) is an exceedingly rare tumor with limited mention in scientific literature. The clinical manifestations of PPL are often nonspecific, making it challenging to distinguish this disease from other pancreatic-related diseases. Chemotherapy remains the primary treatment for these individuals. CASE SUMMARY In this case study, we present the clinical details of a 62-year-old woman who initially presented with vomiting, abdominal pain, and dorsal pain. On further evaluation through positron emission tomography-computed tomography, the patient was considered to have a pancreatic head mass. However, subsequent endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA) revealed that the patient had pancreatic peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS). There was a substantial decrease in the size of the pancreatic mass after the patient underwent a cycle of chemotherapy comprised of brentuximab vedotin, decitabine, and oxaliplatin (brentuximab vedotin and Gemox). The patient had significant improvement in radiological findings at the end of the first cycle. CONCLUSION Primary pancreatic PTCL-NOS is a malignant and heterogeneous lymphoma, in which the clinical manifestations are often nonspecific. It is difficult to diagnose, and the prognosis is poor. Imaging can only be used for auxiliary diagnosis of other diseases. With the help of immunostaining, EUS-FNA could be used to aid in the diagnosis of PPL. After a clear diagnosis, chemotherapy is still the first-line treatment for such patients, and surgical resection is not recommended. A large number of recent studies have shown that the CD30 antibody drug has potential as a therapy for several types of lymphoma. However, identifying new CD30-targeted therapies for different types of lymphoma is urgently needed. In the future, further research on antitumor therapy should be carried out to improve the survival prognosis of such patients.

show abstract

Antineoplastics

2024

Reactions Weekly

View full text Add to dashboard Cite

Primary pancreatic lymphoma: Report of 4 cases with literature review

Cited by 3 publications

References 17 publications

Lymphoproliferative disease: could they be localized in the pancreas?

Lymphoproliferative disease: could they be localized in the pancreas?

Primary pancreatic peripheral T-cell lymphoma: A case report

Antineoplastics

Contact Info

Product

Resources

About